PARP1 and cancer: This characterizes the rationale for PARP inhibitors (PARPi) development, being the first clinically approved drug developed to specifically target the DNA repair mechanisms, especially in cancers with defects in DNA damage repair systems, particularly, BRCA1 and BRCA2 mutations [65,74].